Viridian Therapeutics

VRDN

Market cap $1.53B

Overview Fund Activity

18.71 USD

+0.05

0.27%

At close Updated Sep 17, 12:10 PM EDT

1 day

0.27%

5 days

-5.7%

1 month

3.31%

3 months

26.08%

6 months

16.65%

Year to date

-5.31%

1 year

-11.66%

5 years

41.74%

10 years

-93.65%

About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Employees: 143

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 8 [Q1] → 10 (+2) [Q2]

7% more capital invested

Capital invested by funds: $1.23B [Q1] → $1.32B (+$90.3M) [Q2]

3.77% more ownership

Funds ownership: 112.12% [Q1] → 115.89% (+3.77%) [Q2]

3% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 64

3% less funds holding

Funds holding: 176 [Q1] → 170 (-6) [Q2]

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

70% less call options, than puts

Call options by funds: $1.81M | Put options by funds: $5.96M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$26

39% upside

Avg. target

$33

74% upside

High target

$41

119% upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Goldman Sachs Richard Law	$30	Buy Maintained	7 Aug 2025
RBC Capital Lisa Walter	$41	Outperform Maintained	7 Aug 2025
Wells Fargo Derek Archila	$26	Equal-Weight Maintained	7 Aug 2025
Oppenheimer Leland Gershell	$32	Outperform Maintained	7 Aug 2025
Needham Serge Belanger	$34	Buy Maintained	6 Aug 2025

See Analyst Rankings

Financial journalist opinion

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that enrollment is complete in REVEAL-1 and REVEAL-2, phase 3 clinical trials for VRDN-003 in patients with active and chronic TED, respectively. VRDN-003 is a subcutaneously delivered, half-life extended, monoclonal antibody targeting the insulin-like growth fa.

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 139,600 shares of the company's common stock to 4 new employees (th.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday.

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

The Motley Fool

Viridian (VRDN) Q2 Net Loss Widens 55%

Viridian (VRDN) Q2 Net Loss Widens 55%

Viridian (VRDN) Q2 Net Loss Widens 55%

Zacks Investment Research

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.02 per share a year ago.

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2025. “Veligrotug's recent Breakthrough Therapy Designation as well as the continued and consistent performance of veligrotug across all of the endpoints and timepoints in our.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 181,450 shares of the company's common stock to 4 new employees (th.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. (“Kissei”) to develop and commercialize veligrotug and VRDN-003 in Japan. Both molecules are anti-insulin-like growth factor-1 receptor (IGF-1R) a.

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 175,000 shares of the company's common stock to one new employee (t.

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics: The Song Remains The Same

Viridian Therapeutics is targeting thyroid eye disease with late-stage assets, and shares have dropped significantly over the past six months, despite no major negative news. Analyst sentiment remains bullish, with multiple Buy ratings and price targets far above current levels. The company has a couple of milestones upcoming in 2025 and more pivotal once scheduled in 2026 including a likely FDA approval.

Viridian Therapeutics: The Song Remains The Same

See News Rankings

Charts implemented using Lightweight Charts™